DiabetesSARC-ENDONCT07703683
Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine Diseases
An observational study of Diabetes and Obesity & Overweight, run by Cliniques universitaires Saint-Luc- Université Catholique de Louvain at 1 site in Belgium.
Trial summary
Prospective, observational, single-center, study evaluating the prevalence of sarcopenia / sarcopenic obesity in individuals with metabolic and / or endocrine diseases, as well as the potential role of myokines as biomarkers or drivers of sarcopenia / sarcopenic obesity in this population. . Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diabetes, Obesity & Overweight, Cushing Syndrome
- What is being tested?
- GLP-1 Receptor Agonists
- How many people
- 100 participants
- Where
- 1 siteBelgium
- Study dates
- 19 Feb 2026to 31 Dec 2056
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: People with metabolic or endocrine diseases
Who may be able to join
- Metabolic or endocrine disease
Who cannot join
- Known myopathy
- Systemic steroid use (> 1 mg/kg hydrocortisone) or exogenous Cushing's syndrome
- Psychological, family, sociological or geographical conditions that could potentially limit compliance with the study protocol
- History of cancer within the five years prior to the study or Cushing's syndrome due to ACTH-secreting tumor
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Belgium1 site, 1 recruiting
- Recruiting
Cliniques Universitaires Saint-Luc
Woluwe-Saint-Pierre - Sint-Pieters-Woluwe, 1150
Laura Orioli, MD, PhD, +32494507621, laura.orioli@saintluc.uclouvain.be
About this study
Prospective, observational, single-center, study evaluating the prevalence of sarcopenia / sarcopenic obesity in individuals with metabolic and / or endocrine diseases, as well as the potential role of myokines as biomarkers or drivers of sarcopenia / sarcopenic obesity in this population.
.
- Conditions
- Diabetes, Obesity & Overweight, Cushing Syndrome, Metabolic Diseases, Endocrine Diseases, Sarcopenia
- Being tested
- GLP-1 Receptor Agonists
- Medical subject headings
- Diabetes Mellitus, Obesity, Overweight, Cushing Syndrome, Metabolic Diseases, Endocrine System Diseases, Sarcopenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GLP-1 Receptor AgonistsDrug
Also called GLP-1/GIP dual agonists
Participants receive GLP-1 RA or GLP-1/GIP dual agonists as part of their standard care for overweight or obesity
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of sarcopenia / sarcopenic obesity
Measured: From February 2026 to december 2056
Secondary outcomes (4)
Myokines levels in serum or plasma
Myokines levels in serum or plasma as measured by ELISA
Measured: February 2026 to December 2056
Myokine expression
Myokine expression in muscle as measured by RT-qPCR or RNA-Seq
Measured: February 2026 to December 2056
Prevalence of MASLD
MASLD as evaluated by Fibroscan, based on controlled attenuation parameter (CAP, in decibels per meter) as a marker of hepatic steatosis
Measured: March 2026 to December 2056
Prevalence of MASH
Prevalence of MASH as evaluated by Fibroscan, based on Liver stiffness measurement (LSM, in kilopascals) as a surrogate of liver fibrosis
Measured: March 2026 to December 2056
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2026
- Study start19 Feb 2026
- Primary completion31 Dec 2056 (estimated)
- Study completion31 Dec 2056 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DiabetesStudies of the same condition, open and under way.
- More trials run by Cliniques universitaires Saint-Luc- Université Catholique de LouvainThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07703683
- Sponsor's protocol ID
- 2025/29OCT/445
- Acronym
- SARC-ENDO
- Status last verified
- May 2026
- First submitted
- 15 May 2026
- Last updated
- 14 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine Diseases
- ClinicalTrials.gov ID
- NCT07703683
- Acronym / sponsor ID
- SARC-ENDO / 2025/29OCT/445
- Conditions
- Diabetes, Obesity & Overweight, Cushing Syndrome, Metabolic Diseases, Endocrine Diseases, Sarcopenia
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de LouvainUniversity, hospital or other
- Study start
- 19 Feb 2026 (actual)
- Primary completion
- 31 Dec 2056 (estimated)
- Study completion
- 31 Dec 2056 (estimated)
- First posted
- 14 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Prospective, observational, single-center, study evaluating the prevalence of sarcopenia / sarcopenic obesity in individuals with metabolic and / or endocrine diseases, as well as the potential role of myokines as biomarkers or drivers of sarcopenia / sarcopenic obesity in this population.
.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- People with metabolic or endocrine diseases
Key inclusion criteria (1 listed)
- Metabolic or endocrine disease
Key exclusion criteria (4 listed)
- Known myopathy
- Systemic steroid use (> 1 mg/kg hydrocortisone) or exogenous Cushing's syndrome
- Psychological, family, sociological or geographical conditions that could potentially limit compliance with the study protocol
- History of cancer within the five years prior to the study or Cushing's syndrome due to ACTH-secreting tumor
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GLP-1 Receptor AgonistsAlso: GLP-1/GIP dual agonistsParticipants receive GLP-1 RA or GLP-1/GIP dual agonists as part of their standard care for overweight or obesity | Drug | – |
Primary outcome
Prevalence of sarcopenia / sarcopenic obesity
Time frame: From February 2026 to december 2056
4 secondary outcomes
Myokines levels in serum or plasma
Time frame: February 2026 to December 2056
Myokine expression
Time frame: February 2026 to December 2056
Prevalence of MASLD
Time frame: March 2026 to December 2056
Prevalence of MASH
Time frame: March 2026 to December 2056
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
Hyperglycaemia (Non Diabetic), Prediabetes
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diabetes and Obesity & Overweight, run by Cliniques universitaires Saint-Luc- Université Catholique de Louvain at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Laura Orioli, MD, PhD (+32494507621, laura.orioli@saintluc.uclouvain.be), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of sarcopenia / sarcopenic obesity (time frame: From February 2026 to december 2056). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2026.